1. BRAVISSIMO: 12-month results from a large scale prospective trial.
- Author
-
Bosiers, M, Deloose, K, Callaert, Julie, Maene, L, Beelen, R, Keirse, Marc M.J.N.C., Verbist, J., Peeters, P, Schroë, H, Lauwers, G, Lansink, W, Vanslembroeck, K, D'archambeau, O, Hendriks, John, Lauwers, P, Vermassen, Frank, Randon, Caren, Van Herzeele, I, De Ryck, Frederic F.D., De Letter, J, Lanckneus, M, Van Betsbrugge, M, Thomas, B, Deleersnijder, R, Vandekerkhof, J, Baeyens, I, Berghmans, Thierry, Buttiens, J, Van Den Brande, Paul, Debing, Erik, Rabbia, C, Ruffino, A, Tealdi, D, Nano, G, Stegher, S, Gasparini, D, Piccoli, G, Coppieters De Gibson, Arnold G., Silingardi, R, Cataldi, V, Paroni, G, Palazzo, V, Stella, A, Gargiulo, Miriam, Muccini, N, Nessi, F, Ferrero, E, Pratesi, C, Fargion, A, Chiesa, R, Marone, E, Bertoglio, L, Cremonesi, A, Dozza, L, Galzerano, G, De Donato, G, Setacci, C., Bosiers, M, Deloose, K, Callaert, Julie, Maene, L, Beelen, R, Keirse, Marc M.J.N.C., Verbist, J., Peeters, P, Schroë, H, Lauwers, G, Lansink, W, Vanslembroeck, K, D'archambeau, O, Hendriks, John, Lauwers, P, Vermassen, Frank, Randon, Caren, Van Herzeele, I, De Ryck, Frederic F.D., De Letter, J, Lanckneus, M, Van Betsbrugge, M, Thomas, B, Deleersnijder, R, Vandekerkhof, J, Baeyens, I, Berghmans, Thierry, Buttiens, J, Van Den Brande, Paul, Debing, Erik, Rabbia, C, Ruffino, A, Tealdi, D, Nano, G, Stegher, S, Gasparini, D, Piccoli, G, Coppieters De Gibson, Arnold G., Silingardi, R, Cataldi, V, Paroni, G, Palazzo, V, Stella, A, Gargiulo, Miriam, Muccini, N, Nessi, F, Ferrero, E, Pratesi, C, Fargion, A, Chiesa, R, Marone, E, Bertoglio, L, Cremonesi, A, Dozza, L, Galzerano, G, De Donato, G, and Setacci, C.
- Abstract
The BRAVISSIMO study is a prospective, non-randomized, multi-center, multi-national, monitored trial, conducted at 12 hospitals in Belgium and 11 hospitals in Italy. This manuscript reports the findings up to the 12-month follow-up time point for both the TASC A&B cohort and the TASC C&D cohort. The primary endpoint of the study is primary patency at 12 months, defined as a target lesion without a hemodynamically significant stenosis on Duplex ultrasound (>50%, systolic velocity ratio no greater than 2.0) and without target lesion revascularization (TLR) within 12 months. Between July 2009 and September 2010, 190 patients with TASC A or TASC B aortoiliac lesions and 135 patients with TASC C or TASC D aortoiliac lesions were included. The demographic data were comparable for the TASC A/B cohort and the TASC C/D cohort. The number of claudicants was significantly higher in the TASC A/B cohort, The TASC C/D cohort contains more CLI patients. The primary patency rate for the total patient population was 93.1%. The primary patency rates at 12 months for the TASC A, B, C and D lesions were 94.0%, 96.5%, 91.3% and 90.2% respectively. No statistical significant difference was shown when comparing these groups. Our findings confirm that endovascular therapy, and more specifically primary stenting, is the preferred treatment for patients with TASC A, B, C and D aortoiliac lesions. We notice similar endovascular results compared to surgery, however without the invasive character of surgery., info:eu-repo/semantics/published
- Published
- 2013